Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276) has secured clinical trial approval from the National Medical Products Administration (NMPA) for its investigational therapy HRS-1167, which will be evaluated in combination with SHR-A1921, bevacizumab, or abiraterone plus prednisone/prednisolone for the treatment of advanced solid tumors.
HRS-1167 is a second-generation PARP inhibitor designed to target homologous recombination repair defect (HRR) positive tumors, including breast, ovarian, prostate, and pancreatic cancers associated with BRCA mutations. It boasts superior selectivity and affinity for PARP1 compared to first-generation inhibitors and has the unique capability to induce DNA capture. Notably, no comparable product has been approved globally.
SHR-A1921, an antibody-drug conjugate (ADC) that targets TROP-2, functions by binding to tumor cell surface antigens, allowing for internalization and subsequent release of cytotoxic agents that selectively kill cancer cells.- Flcube.com
